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Abstract
Background: The optimal protocol for
125I-transperineal prostatic brachytherapy (TPPB) in intermediate-risk prostate
cancer (PCa) patients remains controversial. Data on the efficacy of combining androgen-deprivation therapy (ADT)
with
125I-TPPB in this group remain limited and consequently the guidelines of the American Brachytherapy Society
(ABS) provide no firm recommendations.
Methods/Design: Seed and Hormone for Intermediate-risk Prostate Cancer (SHIP) 0804 is a phase III, multicenter,
randomized, controlled study that will investigate the impact of adjuvant ADT following neoadjuvant ADT and
125I-
TPPB. Prior to the end of March, 2011, a total of 420 patients with intermediate-risk, localized PCa will be enrolled
and randomized to one of two treatment arms. These patients will be recruited from 20 institutions, all of which
have broad experience of
125I-TPPB. Pathological slides will be centrally reviewed to confirm patient eligibility. The
patients will initially undergo 3-month ADT prior to
125I-TPPB. Those randomly assigned to adjuvant therapy will
subsequently undergo 9 months of adjuvant ADT. All participants will be assessed at baseline and at the following
intervals: every 3 months for the first 24 months following
125I-TPPB, every 6 months during the 24- to 60-month
post-
125I-TPPB interval, annually between 60 and 84 months post-
125I-TPPB, and on the 10th anniversary of
treatment.
The primary endpoint is biochemical progression-free survival (BPFS). Secondary endpoints are overall survival (OS),
clinical progression-free survival, disease-specific survival, salvage therapy non-adaptive interval, acceptability
(assessed using the international prostate symptom score [IPSS]), quality of life (QOL) evaluation, and adverse
events. In the correlative study (SHIP36B), we also evaluate biopsy results at 36 months following treatment to
examine the relationship between the results and the eventual recurrence after completion of radiotherapy.
Discussion: These two multicenter trials (SHIP0804 & SHIP36B) are expected to provide crucial data regarding the
efficacy, acceptability and safety of adjuvant ADT. SHIP36B will also provide important information about the
prognostic implications of PSA levels in intermediate-risk PCa patients treated with
125I-TPPB.
Trial registration: NCT00664456, NCT00898326, JUSMH-BRI-GU05-01, JUSMH-TRIGU0709
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Studies show improved outcomes when androgen-
deprivation therapy (ADT) is included in the therapeu-
tic regimen for men with intermediate-risk prostate
cancer [1], and available data provide stronger support
for the benefits of ADT than for those of radiation
dose escalation in patients with intermediate-risk dis-
ease [1]. In order to obtain further gain, five phase III
clinical trials (RTOG0232, RTOG0815, NCT00890006,
NCT00388804, NCT00005044) examining combined
use of external beam radiation (EBRT) and ADT in
intermediate-risk patients are being planned or cur-
rently in progress [2,3].
125I-transperineal prostatic brachytherapy (TPPB) was
added to the Japanese armamentarium for treatment of
localized PCa in 2003 [4]. Since then, more than 5,000
patients have undergone this procedure. However, the
indication for brachytherapy in intermediate-risk
patients remains controversial. TPPB alone is considered
inadequate for these patients due to possible extrapro-
static extension. Retrospective studies have suggested
that ADT can improve outcomes in intermediate-risk
PCa patients treated with TPPB [1]. There are, however,
no reported prospective studies documenting the effec-
tiveness of adjuvant ADT with TPPB for intermediate-
risk patients. Such prospective clinical trials are clearly
needed. In the present paper, we describe our study pro-
tocol for a phase III, multicenter, randomized, con-
trolled study of TPPB with or without adjuvant ADT in
patients with intermediate-risk PCa.
Adjuvant ADT is significantly associated with adverse
events. The PROST-QA study prospectively measured
patient-reported quality of life outcomes before and
after prostate cancer treatment [5]. Sexual function was
persistently worse among radiation patients who
received ADT than among those who did not. Vitality
and other outcomes related to hormonal therapy (e.g.,
fatigue, weight change, gynecomastia, depression, and
h o tf l a s h e s )w e r ea l s ow o r s ei nt h eA D Tp a t i e n t s .
Furthermore, symptoms persisted after radiotherapy for
up to two years despite < 1 year of ADT [5]. Thus,
patients at intermediate risk who already face the
dilemma of choosing between treatment modalities have
their choice further complicated by the adverse event
profile of ADT and recommending this therapy may not
be appropriate until we have firmer evidence of its bene-
fit. The present trial (SHIP0804) is also expected to pro-
vide crucial data regarding acceptability (assessed using
the international prostate symptom score [IPSS]) and
quality of life (QOL).
For assessment of PCa treatment efficacy, biochemical
failure is a rational early endpoint. Numerous investigators
in the PSA era have demonstrated the importance of bio-
chemical outcome following treatment. A definition of
PSA nadir level + 2 ng/mL, which is adopted in the pre-
sent study, was recently proposed as the recommended
definition of biochemical failure [6]. This definition
reduces misinterpretation of unstable PSA status, such as
that due to the bounce phenomenon, and eliminates back-
dating of progression to preceding measurements.
On the other hand, it was previously reported that the
correlation between biopsy results at 6-36 months after
completion of radiotherapy and the eventual develop-
ment of recurrence after completion of radiotherapy was
highly significant retrospectively [7]. In a correlative
study (SHIP36B), the relationship between PSA levels
and biopsy results 36 months after treatment will be
investigated. SHIP36B will also provide important infor-
mation about the prognostic implications of PSA levels
in intermediate-risk PCa patients treated with TPPB.
As mentioned above, the optimal protocol for
125I-
transperineal prostatic brachytherapy (TPPB) in inter-
mediate-risk prostate cancer (PCa) patients remains
controversial. In the present paper, we describe our
study protocols for a phase III, multicenter, randomized,
controlled study of TPPB with or without adjuvant ADT
in patients with intermediate-risk PCa (SHIP0804), and
to examine the relationship between PSA levels and
biopsy results 36 months after treatment (SHIP36B).
Methods/Design
Aim of the study
To examine the effect of adjuvant luteinizing hormone-
releasing hormone-agonist (LHRHa) therapy (SHIP0804)
and to examine biopsy results at 36 months after bra-
chytherapy (SHIP36B) for intermediate-risk PCa patients
who have received 3-month neoadjuvant LHRHa fol-
lowed by
125I-TPPB.
Study design
The present investigation is a phase III, multicenter,
randomized, controlled study of ADT and TPPB for
patients with untreated intermediate-risk PCa (Figure 1).
All patients are randomized to one of two treatment
arms in which patients either do or do not receive 9-
month adjuvant therapy with a LHRHa following
125I-
TPPB. Prior to
125I-TPPB, all patients undergo 3-month
LHRHa therapy, which consists of subcutaneous gosere-
lin acetate, 3.6 mg/mo, or leuprolide acetate, 3.75 mg/
mo. In a correlative study (SHIP36B), the relationship
between PSA levels and biopsy results 36 months after
treatment will be investigated.
Additional measures
Two validated QOL questionnaires, the SF-8™, which has
been translated into Japanese and is stored in the PBRN
database (SQL Server 7.0), and the Expanded Prostate
Cancer Index Composite (EPIC), will be administered to
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and psychosocial well-being.
Site selection
For an institution to participate, the institution’s attend-
ing physicians must:
a. Acquire certified documentation of participation in
the Japanese Brachytherapy Scientific Meeting’st r a i n i n g
session for the
125I-TPPB procedure.
b. Have experience with
125I-TPPB in at least 50
patients.
c. Regularly perform
125I-TPPB procedures.
Eligibility criteria - Inclusion criteria
Patients must:
a. Be 20 to 75 years of age, with a definitive histologi-
cal diagnosis of PCa by needle biopsy.
b. Have intermediate-risk PCa according to D’Amico’s
stratification [8]. In this stratification, patients with clini-
cal stage T1c or T2a [9], PSA ≤ 10 ng/mL and biopsy
Gleason score ≤ 6 are defined as low-risk, and patients
with ≥ T 2 c ,aP S A>2 0n g / m Lo rab i o p s yG l e a s o n
score ≥ 8 are defined as high-risk. The remaining
patients are defined as the intermediate-risk group.
c. Be previously untreated.
Figure 1 Study design of SHIP0804 and SHIP36B. ADT, androgen deprivation therapy, TPPB, transperineal prostatic brachytherapy.
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renal function in laboratory tests within two weeks prior
to registration.
a) Leukocyte count ≥ 2,000/μL
b) Hemoglobin level ≥ 10.0 g/dL
c) Platelet count ≥ 10.0 × 10
4/μL
d) Serum creatinine level ≥ 2.0 mg/dL
e) ALT and AST levels ≥ 100 IU/L
e. Have an expected survival time of three months or
longer from the start of the treatment.
f. Agree in writing to participate in this clinical study
after receiving adequate explanation.
Eligibility criteria - Exclusion criteria
Patients are ineligible if they:
a. Have previously received surgery for PCa.
b. Have PSA > 20 ng/mL.
c. Have a biopsy Gleason score ≥ 8.
e. Exhibit clinical stage ≥ T2c.
f. Have a second cancer that requires treatment.
g. Have poorly-controlled hypertension (diastolic pres-
sure ≥ 120 mmHg)
h. Have a severe psychiatric disorder, including schizo-
phrenia and dementia.
i. Have poorly-controlled diabetes.
j. Are using steroid drugs other than topical
ointments.
k. Are using antiandrogenic therapy.
l. Are for any other reason considered by a Principal
Investigator or Clinical Investigator to be inappropriate
for participation in the present study.
Informed Consent - Ethics Approval
The study was conducted in accordance with the Hel-
sinki Declaration of 1975, as revised in 2000. All treat-
ments for PCa are undertaken following written
informed consent, and further consent is obtained for
procedures to confirm the diagnosis of intermediate-risk
category. This study received approval from the Founda-
tion for Biomedical Research and Innovation, Transla-
tional Research Informatics Center (TRI) ethical review
committee (approval No. 07-05, date Feb 8, 2008) and
the institutional ethics committees of the participating
facilities.
Methods of recruitment and random allocation
Recruitment of patients is supported by the Seed and
Hormone for Intermediate-risk Prostate Cancer Study
Group (SHIP). Recruiting began in April, 2008, and is
planned for completion by March, 2011. Initial recruit-
ment is through the secretariat division of SHIP. All
prostatic biopsy histological slides of newly diagnosed
PCa since the study was initiated have been reviewed by
central pathologists, with patient eligibility being deter-
mined at the time of review. Eligible patients are ran-
domly assigned to one of two treatment arms through
the data center at the TRI. Randomization is done cen-
trally using a minimization method to obtain good
between-group balance for factors including age cate-
gory (< 70/≥ 70), PSA category (< 10/≥ 10 ng/mL) and
institutions.
Central review of the pathological diagnosis
Following enrolment of the patients, biopsy specimens
are collected and forwarded to the central pathology
group for review. Three uropathologists review the
pathology specimens and classify each according to the
modified Gleason grading system proposed by the Inter-
national Society of Urological Pathology (ISUP) [10]. All
cases are reviewed independently without clinical infor-
mation and decisions are made by consensus.
Technique of
125I-TPPB
125I-TPPB for all patients is administered using an ultra-
sound-guided technique with the Mick applicator [4].
The implant is planned to deliver a dose of at least
144Gy to the clinical target volume, which includes the
prostate gland and treatment margin [11]. Although
individual technical aspects are institution-dependent,
efforts are made to assure optimal quality control of the
radiation dose. Computed tomography images, taken at
2-5 mm intervals, are obtained one month after
125I-
TPPB to determine the extent of edema. Dose-volume
histograms for the prostate, urethra, and rectum are
computed to obtain post-planning distribution data.
V100 and D90 should be over 95% and 144Gy respec-
tively for the clinically targeted volume [11,12]. We
organized a quality control committee for this study
with the aim of assessing inter-institutional variance of
post-implant dosimetry. This board will meet regularly
while this protocol is running to monitor and compare
dosimetry. Results of the comparative analysis will be
reported separately.
Data collection
This design was chosen to ensure accurate, standardized
and high-quality data collection. All patients giving writ-
ten informed consent to the study are asked to complete
a short family history and epidemiology questionnaire.
Electronic Data Capture (EDC) systems are used to col-
lect clinical data in electronic format, with clinical data
being obtained from patient medical records by the TRI.
A follow-up data form is completed by the Clinical
Trials Practitioner (CTP) at diagnosis, 3 months, 6
months, 9 months, 12 months, 15 months, 18 months,
21 months, 24 months, and then every 6 months until
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pleted annually until 84 months from the date of
125I
seed implantation. These forms capture information
regarding patient characteristics, disease presentation,
diagnosis and treatment, PSA, recurrence and survival.
Annual follow up is continued until death, loss to follow
u po rt h ee n do ft h ea c t i v ep h a s eo ft h es t u d y( M a r c h ,
2021).
Definition of endpoints
The primary endpoint is biochemical progression-free
survival (BPFS). Biochemical progression is defined as
an increase in prostate specific antigen (PSA) of 2 ng/
mL or greater from the nadir value following treatment.
Secondary endpoints include OS, clinical progression-
free survival (local, distant failure), disease-specific survi-
val, salvage therapy non-adaptive interval, acceptability
(assessed by the international prostate symptom score
[IPSS]), quality of life (QOL) and adverse events. Overall
survival and progression-free survival are respectively
calculated from the 1st day of treatment to any death,
or to identification of disease progression or death.
Local progression is defined as reappearance of local
tumorat the primary site. Reappearance of local tumor
will be confirmed by rectal examination and imaging
studies such as magnetic resonance imaging or com-
puted tomography. The primary endpoint of a correla-
tive study (SHIP36B) is the biopsy results at 36 months
following treatment to examine the relationship between
results and eventual recurrence after completion of
radiotherapy.
Planned statistical analyses
It has been shown that the 5-year BPFS rate ranges from
63% to 98% in patients with intermediate-risk PCa who
undergo radiotherapy [13,14]. Assuming that the 7-year
BPFS rate of the control group is 60% (the 5-year BPFS
is about 69%) and the expected 7-year BPFS rate of the
adjuvant ADT group is 73.6% (i.e. hazard ratio is 0.6),
190 patients for each group are needed to detect a sig-
nificant difference between treatments by log-rank test
with a significance level of 0.05 and a power of 80%.
Given the further assumption that approximately 10% of
randomized patients will be unevaluable for various rea-
sons, the target sample size was set at 210 patients per
group (420 patients total).
Statistical analyses will be performed on an intention-
to-treat basis. Survival curves will be estimated using
the Kaplan-Meier method. To test for differences in
survival curves between the two groups of patients, the
log-rank test will be used. The hazard ratio will be esti-
mated using the Cox proportional hazard model. The
longitudinal change of QOL scores (IPSS, SF-8, and
EPIC) between diagnosis and 60 months following
125I-
TPPB will also be compared between groups. Patients
will be evaluated for toxicity, graded according to the
National Cancer Institute Common Toxicity Criteria
version 3.0 [15]. For all patients, the incident proportion
of grade 3 adverse events will be compared between
groups by Fisher exact test. All tests will be two-sided,
and a value of 0.05 will be considered statistically signifi-
cant. Five years after the last patient is recruited, an
interim analysis will be performed and the results will
be reported to the Independent Data Monitoring
Committee.
Patient enrollment and anticipated completion of
enrollment
Monthly enrollment was moderately below goal, but
cumulative enrollment reached 181 cases in December,
2009. Slow enrollment may reflect the relatively low fre-
quency of PCa patients with intermediate-risk [4]. Our
current expectation is that the final patient will be
enrolled by March, 2011; the study will be clinically
complete by 2021 and results will be available during
the first quarter of 2022.
Discussion
There are considerable data supporting the use of adju-
vant ADT with EBRT in selected patients with PCa, par-
ticularly those with locally advanced, unfavorable-risk
disease [1,16,17]. Presently, however, the effect of com-
bination therapy with ADT in localized prostate cancer
remains controversial. A prospective randomized con-
trolled trial including 206 intermediate- to high-risk,
localized PCa patients (PSA ≥ 10 ng/mL, Gleason score
≥ 7, or radiographic evidence of extraprostatic disease)
indicated 6-month ADT (neoadjuvant, concurrent and
adjuvant) in combination with EBRT led to significantly
higher overall survival than RT alone [17]. However, the
study enrolled a mixed population of patients at varying
risks of disease recurrence, complicating extrapolation
of the results to any single risk group.
The ABS recommends neoadjuvant ADT in conjunction
with TPPB for downsizing the prostatic gland when the
initial size surpasses 60 cc, but provides no clear indication
for using ADT adjuvantly in intermediate- to high-risk dis-
ease. The liberal use of neoadjuvant therapy can be a con-
founder when evaluating efficacy of ADT in combination
with TPPB within a certain risk category. The uniformly
used neoadjuvant ADT and the consequent downsizing of
the gland will facilitate recruitment and reduce potential
bias in patient selection in our randomized trial. Since the
participating institutions were overloaded with a long
waiting list of patients for TPPB, it was considered more
practical to have certain period of neoadjuvant ADT prior
to TPPB. All patients are thus planned to undergo fixed-
term, 3-month neoadjuvant ADT.
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for combined use of ADT with TPPB and/or EBRT in
PCa patients with unfavorable features [18,19]. However,
there are no reports of prospective studies documenting
the effectiveness of adjuvant ADT with TPPB for inter-
mediate-risk PCa patients. The study by D’Amico et al
showed the benefits of a relatively short, 6-month
course of ADT [17]. We accordingly set the adjuvant
ADT administration period at 9 months to facilitate
detection of any differences between groups receiving or
not receiving this therapy. Adverse effects will be
assessed using validated questionnaires.
In intermediate-risk PCa patients, according to Partin’s
table [20], the probabilities for pT3, extracapsular exten-
sion (ECE), seminal vesicle involvement (SVI) and lymph
node (LN) involvement are predicted to be 58 to 82%, 40
to 57%, 11 to 23% and 6 to 29%, respectively. Naito’s
Japanese nomogram predicts the respective correspond-
ing rates as 39 to 76%, 33 to 59%, 5 to 10% and 1 to 7%
[21]. This patient population therefore harbors a definite
risk of pathologically more advanced disease including
the possibility of subclinical metastatic disease. Radiation
dose escalation presumes that higher radiation doses
administered to the prostate and periprostatic area are
more likely to eradicate prostate cancer cells than lower
doses of radiation [22]. However, the high intraprostatic
dose coverage provided by
125I-TPPB may be insufficient
for periprostatic disease [19,23]. Our study design will
provide additional insight regarding the efficacy and lim-
itations of TPPB when adjuvant ADT is applied.
The primary goal of SHIP0804 is to evaluate the effec-
tiveness of adjuvant ADT following TPPB on the 10-
year BPFS endpoint in intermediate-risk PCa. Data from
this clinical trial may also confirm PSA as an appropri-
ate surrogate endpoint after treatment of PCa.
It was reported that the postirradiation biopsy per-
formed at a sufficient interval after radiotherapy can
provide accurate prognostic information useful in the
determination of the success or failure of radiotherapy
in an individual patient as well as the measurement of
overall efficacy of any particular radiotherapeutic regi-
men [7]. In a retrospective analysis, Scardino et al. [7]
previously reported that by analyzing the 140 patients
who had one or more needle biopsies performed 6-36
months after completion of radiotherapy, 32% patients
had one or more biopsies positive for cancer, and con-
cluded that the correlation between biopsy results and
the eventual development of recurrence was highly sig-
nificant. Stone et al. [24] also reported that by analyzing
biopsy results in 508 patients with prostate cancer trea-
ted with brachytherapy, cancer positive biopsy was asso-
ciated with high PSA, stage, risk, and no and low dose
hormonal therapy. Recently, the results of prostate biop-
sies 24 months following radiation were also found to
be strongly predictive of subsequent disease-free survival
in a Canadian randomized trial [25]. In our correlative
study (SHIP36B), histological effects of
125I-TPPB and
ADT in relation to PSA levels and kinetics will be inves-
tigated separately. This exploratory design was deter-
mined since the organizing committee could not reach
the consensus to investigate its impact under rando-
mized scheme. Nevertheless, SHIP36B will provide
important further information about the prognostic
implication of PSA levels in intermediate-risk PCa
patients treated with
125I-TPPB.
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